EP217: Big Alcohol vs. Big Pharma: The Fight for THC
In this episode of the Cannabis Accounting Podcast, host Raymond Guns sits down with Art Massolo, founder of Big Hug Strategies and former President of the US Hemp Roundtable, to break down the battle for THC playing out between big alcohol, big pharma, and the cannabis industry itself.
Art spent 30 years scaling wine brands globally before pivoting into cannabis. As head of business development at Cycling Frog, he helped scale a nationally distributed Delta-9 THC beverage brand through traditional alcohol distribution channels. As former President of the US Hemp Roundtable, he has advocated on the Hill and advised operators through every regulatory turn. Few people have his view of both sides of this battle.
Art breaks down:
🍷 Alcohol's last window to own THC: Art is publicly begging his own industry to move now. If spirits, beer, and wine brands stay on the sidelines, pharma synthesizes THC and takes the category.
💊 The pharma play nobody's watching: Why pharma has both the capital and the momentum to synthesize THC and take the category out from under the current cannabis industry.
🤝 The call to arms: Why Trulieve, Curaleaf, GTI, and the hemp beverage brands should stop fighting each other and unite before pharma writes the rules for all of them.
🧠 Why consumer behavior already moved: 30-second attention spans, less drinking, more supplements, everything online, and mental health as the new north star. The audience is ready. The supply chains aren't.
🌾 The case for industrial hemp: Carbon capture without water. Biofuels, plastics, paper, and clothing, all from one plant. Art on why it should be planted in every state and why it isn't.
Art's analysis is clear: we're still in the first inning. Alcohol still has time to pivot, cannabis and hemp still have time to unite, and pharma is closing fast. The operators who move now will be the ones writing the next chapter.
Subscribe for deep dives on cannabis business, accounting, regs, and growth! 🔥
Art spent 30 years scaling wine brands globally before pivoting into cannabis. As head of business development at Cycling Frog, he helped scale a nationally distributed Delta-9 THC beverage brand through traditional alcohol distribution channels. As former President of the US Hemp Roundtable, he has advocated on the Hill and advised operators through every regulatory turn. Few people have his view of both sides of this battle.
Art breaks down:
🍷 Alcohol's last window to own THC: Art is publicly begging his own industry to move now. If spirits, beer, and wine brands stay on the sidelines, pharma synthesizes THC and takes the category.
💊 The pharma play nobody's watching: Why pharma has both the capital and the momentum to synthesize THC and take the category out from under the current cannabis industry.
🤝 The call to arms: Why Trulieve, Curaleaf, GTI, and the hemp beverage brands should stop fighting each other and unite before pharma writes the rules for all of them.
🧠 Why consumer behavior already moved: 30-second attention spans, less drinking, more supplements, everything online, and mental health as the new north star. The audience is ready. The supply chains aren't.
🌾 The case for industrial hemp: Carbon capture without water. Biofuels, plastics, paper, and clothing, all from one plant. Art on why it should be planted in every state and why it isn't.
Art's analysis is clear: we're still in the first inning. Alcohol still has time to pivot, cannabis and hemp still have time to unite, and pharma is closing fast. The operators who move now will be the ones writing the next chapter.
Subscribe for deep dives on cannabis business, accounting, regs, and growth! 🔥
Loading content...
Read the full transcript
Matterfact has every podcast on Apple Podcasts and Spotify: 700K+ channels, 120M+ episodes.
The candid version is on a podcast,
not the earnings call.
Matterfact turns the conversations your coverage is already having into a searchable, citable record — across every episode, not just this one.